Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
Safety and immunogenicity of multi-antigen AMA1-based vaccines formulated with CoVaccine HT and Montanide ISA 51 in rhesus macaques
Malaria Journal, Volume 10, Article 182, Year 2011
Notification
URL copied to clipboard!
Description
Background: Increasing the breadth of the functional antibody response through immunization with Plasmodium falciparum apical membrane antigen 1 (PfAMA1) multi-allele vaccine formulations has been demonstrated in several rodent and rabbit studies. This study assesses the safety and immunogenicity of three PfAMA1 Diversity-Covering (DiCo) vaccine candidates formulated as an equimolar mixture (DiCo mix) in CoVaccine HT or Montanide ISA 51, as well as that of a PfAMA1-MSP119fusion protein formulated in Montanide ISA 51. Methods. Vaccine safety in rhesus macaques was monitored by animal behaviour observation and assessment of organ and systemic functions through clinical chemistry and haematology measurements. The immunogenicity of vaccine formulations was assessed by enzyme-linked immunosorbent assays and in vitro parasite growth inhibition assays with three culture-adapted P. falciparum strains. Results: These data show that both adjuvants were well tolerated with only transient changes in a few of the chemical and haematological parameters measured. DiCo mix formulated in CoVaccine HT proved immunologically and functionally superior to the same candidate formulated in Montanide ISA 51. Immunological data from the fusion protein candidate was however difficult to interpret as four out of six immunized animals were non-responsive for unknown reasons. Conclusions: The study highlights the safety and immunological benefits of DiCo mix as a potential human vaccine against blood stage malaria, especially when formulated in CoVaccine HT, and adds to the accumulating data on the specificity broadening effects of DiCo mix. © 2011 Kusi et al; licensee BioMed Central Ltd.
Authors & Co-Authors
Asamoah Kusi, Kwadwo Asamoah
Netherlands, Rijswijk
Biomedical Primate Research Centre - Rijswijk
Ghana, Accra
Noguchi Memorial Institute for Medical Research
Remarque, Edmond J.
Netherlands, Rijswijk
Biomedical Primate Research Centre - Rijswijk
Riasat, Vanessa
Netherlands, Rijswijk
Biomedical Primate Research Centre - Rijswijk
Netherlands, The Hague
Hagaziekenhuis
Walraven, Vanessa
Netherlands, Rijswijk
Biomedical Primate Research Centre - Rijswijk
Netherlands, Schiedam
Vlietland Hospital
Thomas, Alan W.
Netherlands, Rijswijk
Biomedical Primate Research Centre - Rijswijk
Faber, Bart W.
Netherlands, Rijswijk
Biomedical Primate Research Centre - Rijswijk
Kocken, Clemens H.M.
Netherlands, Rijswijk
Biomedical Primate Research Centre - Rijswijk
Statistics
Citations: 38
Authors: 7
Affiliations: 4
Identifiers
Doi:
10.1186/1475-2875-10-182
e-ISSN:
14752875
Research Areas
Genetics And Genomics
Infectious Diseases
Maternal And Child Health